ANGPTL4 and lobular neoplasia: Additionally, during follow-up examinations of LN patients, urine ANGPTL4 was found to be present either prior to or concomitantly with worsening of the SLEDAI or rSLEDAI, indicating its reliability and significance as a clinical marker of disease activity and suggesting its utility as a novel urinary biomarker for tracking LN disease activity.